title: Effect of pharmacological treatment of depression on A1C and quality of life in low-income Hispanics and African Americans with diabetes: a randomized, double-blind, placebo-controlled trial.
abstract: OBJECTIVE
  To determine whether pharmacological treatment of depression in low-income minorities with diabetes improves A1C and quality of life (QOL).
  
  
  METHODS
  This was a 6-month, randomized, double-blind, placebo-controlled trial. Patients were screened for depression using Whooley's two-question tool at a county diabetes clinic. Depression was confirmed (or not) with the Computerized Diagnostic Interview Survey (CDIS) software program, and the severity of depression was assessed monthly by the Hamilton Depression Scale (HAM-D). Depressed subjects with A1C levels >or=8.0% were randomly assigned to receive either sertraline or placebo. Diabetes care was provided by nurses following detailed treatment algorithms who were unaware of therapy for depression.
  
  
  RESULTS
  A total of 150 subjects answered positively to at least one question on Whooley's questionnaire. The positive predictive value for depression diagnosed by CDIS was 69, 67, and 84% for positive answers to question 1 only, question 2 only, or both, respectively. Of the 89 subjects who entered the study, 75 completed. An intention-to-treat analysis revealed significant differences between baseline and 6 months in HAM-D and pain scores, QOL, and A1C and systolic blood pressure levels in both groups, with no differences between groups for the first three but a significantly greater decrease with sertraline in A1C and systolic blood pressure levels. Changes in HAM-D scores and A1C levels were significantly correlated in all subjects (P = 0.45 [P < 10(-6)]).
  
  
  CONCLUSIONS
  In this low-income minority population, pharmacological treatment of depression significantly improved A1C and systolic blood pressure levels compared with placebo.
authors.affiliation: Charles Drew University, Los Angeles, California, USA.
authors.forename: Diana
authors.initials: D
authors.lastname: Echeverry
authors.forename: Petra
authors.initials: P
authors.lastname: Duran
authors.forename: Curley
authors.initials: C
authors.lastname: Bonds
authors.forename: Martin
authors.initials: M
authors.lastname: Lee
authors.forename: Mayer B
authors.initials: MB
authors.lastname: Davidson
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use; D001007:Anxiety; D044383:Black People; D001794:Blood Pressure; D001835:Body Weight; D008078:Cholesterol, LDL / Q000097:blood; D003863:Depression / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D048909:Diabetes Complications / Q000097:blood* / Q000523:psychology*; D004311:Double-Blind Method; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006630:Hispanic or Latino; D006801:Humans; D008297:Male; D010919:Placebos; D011237:Predictive Value of Tests; D011788:Quality of Life; D020280:Sertraline / Q000627:therapeutic use; D012725:Sexual Behavior; D011795:Surveys and Questionnaires; D001741:Black or African American
chemical_list: D000928:Antidepressive Agents; D008078:Cholesterol, LDL; D006442:Glycated Hemoglobin; D010919:Placebos; D020280:Sertraline